Stone House Investment Management »

Crispr Therapeutics shares owned by Stone House Investment Management

Quarter-by-quarter ownership of Crispr Therapeutics (CRSP) shares owned by Stone House Investment Management from 13F filings

Historical chart of Stone House Investment Management investment in Crispr Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Crispr Therapeutics held by Stone House Investment Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Crispr Therapeutics by Stone House Investment Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $39k 569 68.16
2023-12-31 $11k 169 62.60
2023-09-30 $8.9k 196 45.39
2023-06-30 $11k 196 56.14
2023-03-31 $8.9k 196 45.23

More positions owned by Stone House Investment Management

Ishares Tr Core S&p500 Etf (IVV)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Ishares Tr Core Total Usd (IUSB)
Procter & Gamble Company (PG)
Ishares Tr Msci Usa Qlt Fct (QUAL)
Blackrock Etf Trust Us Eqt Factor (DYNF)
Ishares Tr Core Msci Total (IXUS)
Ishares Tr S&p 500 Grwt Etf (IVW)
Ishares Tr Eafe Value Etf (EFV)
Ishares Tr Eafe Grwth Etf (EFG)
Ishares Tr S&p 500 Val Etf (IVE)
Ishares Tr Mbs Etf (MBB)
Ishares Tr U.s. Tech Etf (IYW)
Ishares Tr Core Us Aggbd Et (AGG)
Ishares Msci Emrg Chn (EMXC)

View all positions for Stone House Investment Management

Top funds holding Crispr Therapeutics

ARK Investment Management
Sumitomo Mitsui Trust Holdings
Nikko Asset Management Americas
T. Rowe Price Investment Management
BlackRock
FMR
Vanguard Group
NEA Management Company
Citadel Advisors
EcoR1 Capital
Susquehanna International
Morgan Stanley
Bank of America Corporation
Loomis, Sayles and
Dimensional Fund Advisors

View all funds holding Crispr Therapeutics